8-K: Seelos Therapeutics Partners with U.S. Army to Evaluate SLS-002 for PTSD Treatment

Seelos Therapeutics has signed a Material Transfer Agreement with the U.S. Army to evaluate its drug, SLS-002, for the treatment of PTSD in a clinical trial.

Summary

• Seelos Therapeutics has entered into a Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity (USAMMDA).
• The agreement will allow the USAMMDA to evaluate Seelos' drug, SLS-002, for the treatment of Post-Traumatic Stress Disorder (PTSD).
• SLS-002, an intranasal racemic ketamine, will be used in the Department of Defense's Military and Veterans Adaptive Platform Clinical Trial (M-PACT).
• Dosing of the SLS-002 cohort is expected to begin in the fourth quarter of 2024.
• The M-PACT trial is a Phase II randomized, double-blinded, placebo-controlled study.
• The trial will assess the safety, tolerability, and efficacy of multiple treatments for PTSD in active-duty service members and veterans.
• The study includes a 30-day screening period, a 12-week treatment period, and a 4-week safety follow-up.
• Data will be collected to measure changes in PTSD symptom severity using the Clinician-Administered PTSD Scale-5-Revised (CAPS-5-R).
• The trial will also monitor for suicidal thoughts or behaviors using the Columbia Suicide Severity Rating Scale (C-SSRS).
• Approximately 13 million people in the U.S. live with PTSD, and there have been no new drugs approved in the last two decades for this condition.

Sentiment

Score: 7

Explanation: The document is positive due to the partnership with the U.S. Army and the potential for SLS-002 to address an unmet need in PTSD treatment. However, the inherent risks of clinical trials and regulatory approval temper the overall sentiment.

Positives

• The partnership with the U.S. Army provides significant validation for Seelos' SLS-002.
• The inclusion of SLS-002 in the M-PACT trial offers a potential pathway to address the unmet need for PTSD treatments.
• SLS-002's intranasal formulation may offer a rapid onset of benefit with fewer side effects compared to other ketamine administration methods.
• The M-PACT trial's adaptive platform design increases study efficiency by sharing control participants.
• The trial will evaluate multiple pharmacotherapeutic interventions, potentially leading to a better understanding of PTSD treatment options.

Negatives

• The document highlights the lack of new PTSD treatments in the last two decades, indicating a challenging landscape for drug development.
• The trial is still in Phase II, meaning there is no guarantee of success or regulatory approval for SLS-002.
• The document mentions forward-looking statements are subject to risks and uncertainties, which could impact the trial's outcome and timeline.

Risks

• The success of the M-PACT trial is not guaranteed, and the results may not be favorable for SLS-002.
• Regulatory approval for SLS-002 is not assured, even if the trial is successful.
• The company's forward-looking statements are subject to various risks and uncertainties that could affect actual results.
• The company's ability to satisfy closing conditions applicable to the offering could impact the trial.
• General economic and market conditions could impact the company's ability to fund the trial and future development.

Future Outlook

The company anticipates commencing dosing of the SLS-002 cohort in the M-PACT trial in the fourth quarter of 2024 and is hopeful that the trial will demonstrate the efficacy of SLS-002 for PTSD treatment.

Management Comments

• Raj Mehra, Ph.D., Chief Executive Officer of Seelos, stated that the inclusion of SLS-002 in the study is due to the robust amount of anecdotal evidence that ketamine has the potential to be an effective therapeutic for the symptoms of PTSD.
• Raj Mehra also mentioned that their data suggests that the intranasal formulation of SLS-002 could provide a rapid onset of benefit while mitigating the side effects seen through other routes of administration of ketamine.

Industry Context

This announcement is significant as it highlights the ongoing efforts to find new treatments for PTSD, a condition with limited therapeutic options. The use of ketamine, while not new, is being explored in novel ways, such as intranasal administration, to improve efficacy and reduce side effects. This partnership with the U.S. Army also underscores the importance of addressing the mental health needs of military personnel and veterans.

Comparison to Industry Standards

• The M-PACT trial is similar to other adaptive platform trials in that it aims to evaluate multiple treatments simultaneously, increasing efficiency.
• The use of ketamine for PTSD is being explored by other companies, such as Janssen Pharmaceuticals with Spravato (esketamine), but Seelos' intranasal approach is a differentiator.
• The trial's focus on active-duty service members and veterans aligns with the broader industry trend of addressing mental health issues in specific populations.
• The trial's endpoints, including the CAPS-5-R and C-SSRS scales, are standard measures used in PTSD clinical trials.

Stakeholder Impact

• Shareholders may view this partnership positively, potentially increasing the company's stock value.
• Employees may be motivated by the potential to contribute to a significant advancement in PTSD treatment.
• Patients with PTSD and their families may have increased hope for new treatment options.
• The U.S. Army and veterans will benefit from the potential for improved PTSD treatment options.
• The broader medical community will gain valuable insights into the efficacy of ketamine for PTSD.

Next Steps

• Commencement of dosing for the SLS-002 cohort in the M-PACT trial is expected in the fourth quarter of 2024.
• Data collection and analysis will occur throughout the trial, including the 30-day screening, 12-week treatment, and 4-week safety follow-up periods.
• The company will likely provide updates on the trial's progress in future communications.

Key Dates

Keywords

SLS-002, PTSD, ketamine, USAMMDA, M-PACT, clinical trial, intranasal, biopharmaceutical, CNS disorders, suicidality